
Roche’s Fenebrutinib Shows First PPMS Disability Reduction in Over a Decade
Roche’s fenebrutinib becomes the first investigational therapy in over a decade to slow disability progression in primary progressive multiple sclerosis (PPMS) Roche announced today new late-breaking data from the Phase III FENtrepid study showing the investigational Bruton’s tyrosine kinase (BTK)…











